利妥昔单抗化疗后[18F]氟脱氧葡萄糖正电子发射断层扫描预测非霍奇金淋巴瘤治疗的中期和最终结果：一项荟萃分析。

The predictive value of interim and final [18F] fluorodeoxyglucose positron emission tomography after rituximab-chemotherapy in the treatment of non-Hodgkin's lymphoma: a meta-analysis.

机构信息

Department of Nuclear Medicine, Renji Hospital, Jiaotong University, Shanghai 200127, China ; Department of Nuclear Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China.

出版信息

Biomed Res Int. 2013;2013:275805. doi: 10.1155/2013/275805. Epub 2013 Aug 14.

BACKGROUND AND PURPOSE

The aim of this study is to determine the prognostic value of interim and final FDG-PET in major histotypes of B-cell NHL patients treated with rituximab containing-chemotherapy.

METHODS

We searched for articles published in English, limited to lymphoma, rituximab, and FDG-PET, and dedicated to deal with the impact on progression and survival. The log hazard ratios (HR) and their variances were estimated.

RESULTS

A PubMed and Scopus review of published trials identified 13 studies of Progression-free survival (PFS) and overall survival (OS) which were set as the main outcome measures. The combined HRs of I-PET for PFS and OS in DLBCL were 4.4 (P = 0.11) and 3.99 (P = 0.46), respectively. The combined HRs of F-PET for PFS and OS in DLBCL were 5.91 (P = 0.39) and 6.75 (P = 0.92), respectively. Regarding to non-DLBCL with F-PET, the combined HRs of F-PET for PFS and OS were 4.05 (P = 0.79) and 5.1 (P = 0.51), respectively. No publication bias existed.

CONCLUSION

In DLBCL, both I-PET and F-PET can be performed for survival and progression analysis. But in other B-cell subtypes such as follicular lymphoma (FL) and mantle cell lymphoma (MCL), it would be necessary to perform F-PET for predictive purposes.

背景与目的

本研究旨在确定在接受含利妥昔单抗化疗的 B 细胞 NHL 患者中，中期和终期 FDG-PET 的预后价值。

方法

我们搜索了以英语发表的文章，仅限于淋巴瘤、利妥昔单抗和 FDG-PET，并专门研究其对进展和生存的影响。估计了对数危险比（HR）及其方差。

结果

对已发表试验的 PubMed 和 Scopus 综述确定了 13 项关于无进展生存（PFS）和总生存（OS）的研究，这些研究被设定为主要观察指标。在 DLBCL 中，I-PET 对 PFS 和 OS 的合并 HR 分别为 4.4（P = 0.11）和 3.99（P = 0.46）。在 DLBCL 中，F-PET 对 PFS 和 OS 的合并 HR 分别为 5.91（P = 0.39）和 6.75（P = 0.92）。对于非 DLBCL 且有 F-PET 的患者，F-PET 对 PFS 和 OS 的合并 HR 分别为 4.05（P = 0.79）和 5.1（P = 0.51）。没有发表偏倚。